Glioblastoma Multiforme Clinical Trial
Official title:
Pre-operative IL13-PE38QQR Infusion in Patients With Recurrent or Progressive Supratentorial Malignant Glioma: A Phase I/II Study
IL13-PE38QQR is an oncology drug product consisting of IL13 (interleukin-13) and PE38QQR (a
bacteria toxin). IL13-PE38QQR is a protein that exhibits cell killing activity against a
variety of IL13 receptor-positive tumor cell lines indicating that it may show a therapeutic
benefit. In reciprocal competition experiments, the interaction between IL13-PE38QQR and the
IL13 receptors was shown to be highly specific for human glioma cells.
Prior to treatment, patients will have physical and neurologic exams, MRI to measure the
extent of tumor, tumor biopsy, and screening laboratory tests. On Day 1, one or two
catheters will be inserted directly into the tumor, after which a CT scan will be used to
confirm placement. Each patient will receive one IL13-PE38QQR infusion, and the tumor will
be surgically removed on approximately Day 15. In the first group of patients, IL13-PE38QQR
will be infused directly into the tumor for 4 days. Depending on effectiveness or side
effects of the study drug, the duration will be increased stepwise to a maximum of 7 days in
subsequent groups of patients. Once duration of infusion has been determined, the dose of
IL13-PE38QQR will be increased stepwise (in separate groups of patients), depending on
effectiveness or side effects of the study drug. The activity of the drug against the tumor
cells will be judged by examining the removed tumor tissue. Patients will have neurologic
exams and MRI scans immediately after the resection and every eight weeks until disease
progression is observed.
OBJECTIVES:
I. To determine the maximum-tolerated dose (MTD) of IL13-PE38QQR delivered by continuous
infusion via 1 or 2 intratumoral catheters into recurrent or progressive malignant glioma.
II. To determine: the pathologic effect of intratumoral IL13-PE38QQR infusion determined at
Day 15 resection; the neuroradiographic characteristics of convection-enhanced drug
delivery; serum levels of study drug and detect the appearance of antibody to study drug.
III. To determine the proportion of patients surviving at 6 months after continuous
intratumoral IL13-PE38QQR infusion at the MTD, followed by Day 15 resection, of recurrent or
progressive malignant glioma.
IV. To determine: the proportion of patients remaining disease free at 6 months; the time to
progression and overall survival of patients with recurrent or progressive malignant glioma
after infusion of IL13-PE38QQR at the selected dose followed by resection; the pathologic
response rate of recurrent or progressive malignant glioma to IL13-PE38QQR delivered by
continuous intratumoral infusion at the MTD; any additional toxicities of IL13-PE38QQR
administered by stereotaxic catheters into recurrent or progressive malignant glioma at the
MTD; the neuroradiographic characteristics of convection-enhanced drug delivery; serum
levels of study drug and detect the appearance of antibody to study drug.
PROTOCOL OUTLINE: Patients with recurrent or progressive supratentorial malignant glioma who
are considered appropriate for re-operation will be eligible for either phase of the study.
Each patient will have tumor biopsy at study entry, followed by continuous intratumoral
infusion of IL13-PE38QQR via 1 or 2 intratumoral catheters, placed within the enhancing
portion of the tumor. Infusion rate will be held constant at 540 mL/hr (total). Toxicity
will be assessed by clinical neurologic examination and laboratory values. Resection will be
performed on Day 15 (6-13 days after end of infusion). Pathologic evidence of tumor necrosis
will be assessed. Follow-up assessments will include neurologic examinations and MRI scans.
No other anti-tumor treatment will be administered for at least 60 days after resection
(except for progressive disease). Patients will be observed until death.
Phase I: The infusion duration will be escalated first in cohorts of 3-6 patients from 51.8
mL (4 days) to a maximum of 90.7 mL (7 days), to identify a MTD based on infusion duration.
Once duration is determined, IL13-PE38QQR concentration will be escalated in cohorts of 3-6
patients from 90.7 mg to a maximum of 362.8 mg (assuming 7-day infusion) to identify a MTD
based on concentration.
Phase II: Patients will be treated at a selected dose no higher than the MTD to estimate the
proportion of patients surviving at 6 months, time to progression and survival, and
pathologic response rate.
PROJECTED ACCRUAL: In Phase I, 12-48 patients, up to 6 centers in Europe, Israel and North
America. In Phase II, up to 35 efficacy evaluable patients, up to 6 centers.
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05023551 -
Study of DSP-0390 in Patients With Recurrent High-Grade Glioma
|
Early Phase 1 | |
Recruiting |
NCT06059690 -
Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells
|
Phase 1/Phase 2 | |
Recruiting |
NCT04116411 -
A Clinical Trial Evaluating the Efficacy of Valganciclovir in Glioblastoma Patients
|
Phase 2 | |
Terminated |
NCT01902771 -
Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors
|
Phase 1 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Completed |
NCT02386826 -
INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme
|
Phase 1 | |
Completed |
NCT00038493 -
Temozolomide and SCH66336 for Recurrent Glioblastoma Multiforme
|
Phase 2 | |
Withdrawn |
NCT03980249 -
Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of Peripheral Glioma Circulating Tumor Cells
|
Early Phase 1 | |
Recruiting |
NCT01923922 -
CT Perfusion in the Prognostication of Cerebral High Grade Glioma
|
N/A | |
Completed |
NCT01956734 -
Virus DNX2401 and Temozolomide in Recurrent Glioblastoma
|
Phase 1 | |
Completed |
NCT01402063 -
PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation
|
Phase 2 | |
Completed |
NCT01301430 -
Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme.
|
Phase 1/Phase 2 | |
Suspended |
NCT01386710 -
Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT00995007 -
A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas
|
Phase 2 | |
Terminated |
NCT01044966 -
A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma
|
Phase 1/Phase 2 | |
Terminated |
NCT00990496 -
A Study Using Allogenic-Cytomegalovirus (CMV) Specific Cells for Glioblastoma Multiforme (GBM)
|
Phase 1 | |
Completed |
NCT00402116 -
Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients
|
Phase 1/Phase 2 | |
Completed |
NCT00112502 -
Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme
|
Phase 2 | |
Completed |
NCT00504660 -
6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients
|
Phase 2 | |
Recruiting |
NCT05366179 -
Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc
|
Phase 1 |